A score may help predict outlook when lung cancer spreads to the brain
Original title: Optimizing Lung-molGPA-Directed Therapy for EGFR/ALK/ROS1-Wildtype Non-Small Cell Lung Cancer Brain Metastases: Survival Outcomes Analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at real patient records, so it is a way to predict outlook, not a new treatment.
The short version
Doctors tested a score that may help predict how long people live after lung cancer spreads to the brain.
What was studied. Researchers looked back at records of 811 people whose lung cancer had spread to the brain. Their tumors lacked changes in three genes, and the team checked a score called Lung-molGPA.
What they found. Half the people lived longer than 6.9 months, and half lived less. The lowest score group lived 4.81 months, the middle group 7.65 months, and the highest group 16.00 months. Chemotherapy, immunotherapy, and treatment aimed at the brain or chest were each linked to living longer.
What this means, and what it doesn't
What it could mean: This score may help you and your doctor talk about what to expect. It may also help you decide how strong your treatment should be.
What it doesn't mean: This is not a new treatment, and it is not a cure. The score does not change the cancer itself. It only helps predict the outlook. The team looked back at old records, so it cannot prove cause and effect. Your own path can be different from these group numbers.
Source: PubMed, October 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.